Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Launched by UNIVERSITY OF WUERZBURG · Apr 4, 2007

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to treat a rare type of cancer called adrenocortical carcinoma (ACC), which affects the adrenal glands. ACC is known to have a poor outlook, and even after surgery to remove the tumor, many patients see the cancer return. The goal of this study is to explore the potential of immunotherapy, a treatment that helps the body’s immune system fight the cancer more effectively. This research is crucial because we need better treatment options for patients with ACC.

To participate in this trial, you must have a confirmed diagnosis of adrenocortical carcinoma and be in reasonably good health, with a life expectancy of at least six months. The study is open to both patients and healthy individuals who will serve as a control group for comparison. If you join, you’ll be part of an important effort to find new ways to treat ACC, and you can expect to contribute to research that could help many others in the future. It's important to note that individuals with autoimmune diseases or severe health issues may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with histological proven adrenocortical carcinoma
• • healthy persons as control group
• • Life expectancy \> 6 months
• Exclusion Criteria:
• • autoimmune diseases
• • severe clinical condition